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Introduction: The United States has been battling an opioid epidemic for decades. As substance 
use disorders have grown, so too has investigation into treatment options, including integrative 
medicine approaches, for managing opioid withdrawal symptoms (OWS).  
 
Objectives: This systematic review sought to assess the use of integrative medicine approaches 
for the alleviation of OWS in patients dependent on opioids and to summarize the available data.  
 
Methods: The authors searched using synonyms for opioids, substance use disorder, and 
integrative medicine and standardized searches in Embase, PubMed, and Cochrane Library. We 
also hand searched references for systematic reviews. This review did not include articles that 
could not be obtained as full-text publications via interlibrary loan. The review also excluded 
studies with interventions involving acupuncture because multiple systematic reviews on this 
approach already exist. In addition, we also excluded studies of therapy for opioid maintenance. 
We evaluated studies for inclusion based on the Jadad criteria. We compared opioid withdrawal 
outcomes of the studies to determine the efficacy of integrative medicine approaches.  
 
Results: The authors identified a total of 382 unique publications initially for possible inclusion 
through systematic searches. After applying inclusion and exclusion criteria, five studies met 
Jadad criteria. The authors identified an additional two studies for inclusion via hand searching. 
A total of seven studies included interventions consisting of passionflower, weinicom, fu-yuan 
pellet, jinniu capsules, tai-kang-ning, dynorphin, and l-tetrahydropalmatine. Analyzing the 
articles was difficult given the varied scoring methods they used to quantify opioid withdrawal 
 
symptoms and the small sample sizes in the trials. Most showed evidence that supported 
integrative medicine approaches for OWS, although the strength of evidence was limited because 
of sample sizes.  
 
Conclusions: This review found evidence of multiple integrative medicine approaches for opioid 
withdrawal symptoms. Well-designed randomized controlled trials should assess the efficacy of 
integrative medicine for improvement in OWS.   
 
1.0 Introduction:  
In 2017, 191 million opioid prescriptions were written in the United States, the first time 
in ten years that the number of prescriptions written for opioids has been below 200 million per 
year.1 Although progress is being made toward reducing the number of opioids prescribed in the 
United States in light of the opioid epidemic, the opioid prescribing rate remains high at 58.7 
prescriptions per 100 persons.1 As patients and prescribers become increasingly aware of opioid 
use disorder, the identification of effective withdrawal treatments is vital to patient safety and 
comfort.  
Opioid withdrawal symptoms (OWS), including agitation, insomnia, diaphoresis, 
tachycardia, and many others, can be debilitating for many patients.2,3 Symptoms can start as 
early as six hours after the last dose of an opioid and peak around 72 hours after last use.2 
Although OWS may not be life-threatening, unassisted withdrawal can increase the risk of 
relapse.2    
Fear of opioid withdrawal syndrome is a contributing factor to the cycle of abuse in 
individuals who misuse opioids.4 In current practice, opioid withdrawal is managed either 
through the gradual taper of opioid agonists, such as methadone or buprenorphine, or through the 
use of nonopioids, such as clonidine for symptoms.3 Alpha-2 agonists, such as lofexidine, FDA 
approved for OWS, and clonidine, used off label, are sometimes combined with other 
prescription medications to combat specific withdrawal symptoms. For example, 
benzodiazepines are sometimes used for anxiety during withdrawal, although they should be 
used with caution due to known risk of dependence .3 
Although buprenorphine and clonidine are useful in diminishing symptoms, some 
individuals may be interested in integrative medicine approaches for OWS. However, despite 
 
increased interest in integrative medicine for OWS, clear guidance and evidence is lacking. The 
purpose of this systematic review is to identify and evaluate available evidence regarding 
integrative medicine for opioid withdrawal symptoms.   
 
1.1 Methods: 
 1.1.1 Protocol and Registration: The Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses statement was used to conduct this systematic review. 
1.1.2 Literature Search: Three databases, Pubmed, Embase, and Cochrane Library, were 
searched for studies investigating the efficacy of integrative medicine on symptoms of opioid 
withdrawal. The search strategy consisted of using a combination of synonyms from three base-
term categories, including “opioids”, “substance use disorder”, and “integrative medicine”. 
Thirty combinations were searched systematically in each database and included one term from 
the integrative medicine category, one term from the substance-use-disorder category, and the 
standard opioid term sequence. All three categories were connected using the Boolean term 
“AND”. Medical Subject Headings terms were used for Pubmed and Cochrane Library, while 
Emtree terms were used for Embase. Specific terms were determined via the database’s preferred 
terminology. For the integrative-medicine-terms category, the terms “Integrative Medicine”, 
“Complementary Therapies” (Emtree preferred term: “Alternative Medicine”), “Medicine, 
Chinese” (Emtree preferred term: “Chinese Medicine”), “Biological Products” (Emtree preferred 
term: “Natural Products”), and “Herbal Medicine” were searched systematically. For the 
substance-use-disorder category, the terms “Substance Withdrawal Syndrome” (Emtree preferred 
term: “Withdrawal Syndrome”), “Opioid-Related Disorders” (Emtree preferred term: Opioid Use 
Disorder”), and “Substance-Related Disorders” (Emtree preferred term: “Drug Dependence”) 
 
were used. Additionally, “Opioid Withdrawal” and “Detoxification AND Opiate” were used in 
Emtree, but no corresponding term was found in the Medical Subject Headings terms database. 
For the opioid category, “Heroin”, “Morphine”, “Analgesics, Opioid” (Emtree preferred term: 
“Opiate”), “Codeine”, and “Narcotics” (Emtree preferred term: “Narcotic Agent”) were utilized 
for each search as a sequence connected by the Boolean term “OR”. The studies were filtered for 
human subjects, the English language, and the dates January 1, 1968 - January 1, 2019. Articles 
that evaluated the use of acupuncture for opioid withdrawal were excluded from this systematic 
review because of the comprehensive body of data available when compared to the results of 
other, lesser-known integrative medicine approaches. After the initial search outlined above was 
completed, a hand search of the references was conducted to gather any additional potential 
pertinent articles.  
1.1.3 Eligibility: Two authors (CC and CK) used titles and abstracts to screen articles’ 
findings from the three databases. Only randomized controlled trials, case-control studies, or 
cohort studies that evaluated the efficacy of integrative medicine approaches on symptoms of 
opioid withdrawal in adults were included for analysis. Studies that focused on prescription 
medication as the test intervention or focused on symptoms during the maintenance phase of 
treatment were ineligible. Additionally, abstracts or citations were not considered for analysis if 




Fig. 1: Flow diagram of the systematic review process employed in this review.  
1.1.4 Study Selection, Data Extraction, and Analysis: Upon completion of initial 
eligibility screening, two authors (CC and CK) independently scored full-text articles using a 
Jadad scale to assess the quality of the studies. The Jadad scale was chosen because it aims to 
reduce bias in studies by assessing elements of randomization, blinding, and participant 
accountability.5 Studies needed to meet a Jadad score of three or higher to be included.  
Conflicts of any Jadad scores were resolved through independent scoring by two 
additional authors (KW and AH). Once article selection was finalized, two authors (CC and CK) 
each independently extracted data to be subsequently verified by the remaining three authors. 
Researchers assessed study design, the specific integrative medicine approach, comparator 
group(s), participant population, assessment tools used in the trial, outcomes, and results. 
Three hundred and ninety-two unique articles were found during the initial database 
search. After a hand-search for additional articles was completed and exclusion criteria were 
applied to all potential articles, 47 articles were considered for inclusion, but only seven met the 
Jadad criteria and were included in the review.   
Table 1  
Summary of Articles Included in Systematic Review 
Unique articles from initial 
database search 
 (n=392) 
Articles identified for inclusion 
 (n=47) 
Full-text articles included with 
a Jadad > 3 
(n=7) 
Handsearching of articles 
completed and exclusion 
criteria applied 
Studies excluded for not 
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・ After two weeks, survival probability of retention for placebo 
was 100% (95% CI: 100%) and 72% (95% CI: 60-83%) for l-
THP 
○ The dropout rate in the l-THP group was significantly higher 
than placebo  (P<0.0001) [l-THP group went from 61→ 44 
subjects, placebo group remained at 59 subjects] 
・ l-THP group had a higher abstinence rate at 3 month follow-up: 
47.7% (95% CI: 33-67%) vs 15.2% (95% CI: 7-25%);  
P=0.0005 
・ One month of l-THP significantly reduced overall PAWS 
severity; p<0.0001 
○ Mean craving scores at the start of treatment were 41.61 +/- 
2.79 (l-THP versus 41.72 +/- 2.27 (placebo)  
○ Mean craving scores one month after treatment began were 
23.00 +/- 1.91 (l-THP) versus 25.26 +/-1.47 (placebo) 
○ Mean craving scores one month after cessation of treatment 
were 3.5+2.6 (l-THP) versus 7.0+3.5 (placebo); P<0.01 
○ A subanalysis of somatic syndrome, insomnia, and craving 
met statistical significance 
Akhondzadeh 














0.8mg by day 
4,  plus 
Passiflora 
extract, 60 










・ SOWS (scale 
range: 0-30) 
・ Expanded SOWS 




・ Physical symptoms: both groups experienced a decrease in 
scores, however differences between the groups were non-
significant 
・ Mental symptoms: both groups saw improvements in scores 
over time. Statistically significant differences in scores favoring 
passiflora extract were found beginning on the second day and 
continuing to the end of 14 days, though no p value was 
reported 
○ Clonidine group had significantly increased scores compared 
to passiflora extract on days 2, 3, 4, 7, 14 
・ Total scores: significantly decreased by both treatments, but the 
total score by day 14 in the clonidine group was significantly 
higher than the passiflora group (p=0.011)  




・ 30-38 years 








・ Dynorphin IV, 
60 mcg/kg, 
then saline IV 
one  hour later 
(n=6) 
OR 
・ Saline IV then 
dynorphin IV, 
60 mcg/kg,  one 
hour later (n=6) 
2 injections of 
IV saline given 
1 hour apart 
(n=6) 
・ MKHP (scale 
range: no upper 
limit 
・ Decreased withdrawal scores after dynorphin given as the first 
injection (0.01 < P < 0.05) 
○ A sustained decrease during the 1-hr period after saline 
injection [P<0.05 (nurse assessment), P<0.02 (patient 
assessment)] 
・ Decreased score after dynorphin given as the second injection 
whether compared to baseline or to the scores after saline given 
as the first injection 





・ 18-50 years 
・ Opiate 
dependence 





Day 1-3: 2.5g 
three times 
daily  
Day 4-5: 2.0g 
three times 
daily 
Day 6-7: 1.5g 
three times 
daily  
Day 8-9: 1.5g 
twice daily 













Day 8-9: 0.2 or 
0.4mg once 
daily 






・ HAMA (scale 
range: 0-56) 
・ Total opioid withdrawal scale scores decreased for both groups, 
but no significant difference between groups over the ten-day 
course  
・ Main opioid symptom score reduction: no significant 
differences between groups 
・ HAMA: no significant differences in anxiety reductions 
between groups 
○ Day 0: 28.13 +/- 5.42 (Jinniu) versus 27.63 +/- 4.84 
(lofexidine) 
○ Day 5: 9.45 +/- 5.93 (Jinniu) versus 8.96 +/- 5.38 
(lofexidine) 
○ Day 10: 2.58 +/- 2.35 (Jinniu) versus 2.65 +/- 2.39 
(lofexidine) 
 
Wang, X, et al. 




・ 18-55 years 
・ Heroin 
dependence 




Day 1-3: 6.0g 
three times 
daily 
Day 4-6: 8.0g 
three times 
daily 


























scale (scale range: 
unknown)9   
・ HAMA (scale 
range: 0-56) 
・ Daily total withdrawal syndrome rating scale scores: both 
groups had day by day significant decrease ( P =0 .0001) 
○ Both groups met the effective threshold of  >50% reduction 
rate on day 3 (FYP: 58.93%, lofexidine: 60.01%) 
○ No significant difference between groups for daily total 
scores or daily reduction rate 
・ Daily total HAMA score: no significant difference between 
groups  
・ Adverse effects: lofexidine group (42.34%) vs  FYP group 
(14.29%)*; P<0.001 
Kang L, et al. 




・ 18-65 years 
・ Heroin 
dependence 




Day 1-5: 2.0g 
three times daily 
Day 6-7: 1.5g 
three times daily 
Day 8-9: 1.5g 
twice daily 







Day 1: 0.4mg 
twice daily 
Day 2-5: 0.6mg 
three times daily 
Day 6-7: 0.4mg 
three times daily 
Day 8-9: 0.2mg 
or 0.4mg once 





scale (scale range: 
unknown)18 
・ Daily total withdrawal syndrome rating scale scores: both 
groups had day by day significant decrease (P = 0.0001) 
○ Both groups met the effective threshold of  >50% reduction 
rate on day 3 (TKN: 55.94%+16.24%) vs lofexidine: 
64.48+15.06%) 
○ No significant difference between groups for daily total 
scores 
・ Adverse effects: TKN: 62.5% vs. lofexidine: 65.6% 






by DSM-IV  
Inpatient, 
14 days  
WeiniCom, 8-
10 capsules 
four to six 
times daily, 
gradually 
tapered to zero 






y twice daily, 
tapered by 
0.3gm every 






・ Craving Rating 
Scale (0-504) 
・ Side Effects 
Rating Scale (0-
57) 
・ All patients retained for 14 days 
・ Withdrawal symptom scores decreased over time: 
○ Day 5, mean scores: 19.4 for BUP vs. 12.6 for WeiniCom; 
P<0.05 
○ Day 6, mean scores: 16.7 for BUP vs. 9.6 for WeiniCom; 
P<0.05 
○ Day 9, mean scores:15.2 for BUP  vs. 5.2 for WeiniCom; 
P<0.05 
・ The decline in psychological craving was greater for 
WeiniCom:  
○ Day 3: buprenorphine  psychological rating score was 100.0 
versus 43.3 for WeiniCom; P<0.05 
・ Adverse effects were similar between groups 
・ No significant differences in blood, urine, liver, and kidney 
function tests or electrocardiograms between groups 
ATC = addiction treatment center, BUP= Buprenorphine, DSM= Diagnostic and Statistical Manual of Mental Disorders, FYP=Fu-Yuan Pellet  HAMA= 
Hamilton Anxiety Scale19, MKHP=Modified Kolb and Himmelsbach procedure, SOWS= short opioid withdrawal scale, TKN= Tai-Kang-Ning 
*All adverse effects in the study resolved without treatment 
 
1.2 Results: 
Table 1 summarizes findings from the seven trials of integrative medicine identified for 
inclusion. Studies evaluated the use of integrative medicine approaches on multiple aspects of 
opioid withdrawal syndrome, including drug cravings, drug abstinence, and physical symptoms. 
Trials were conducted primarily in an inpatient care setting and used different assessment scales, 
 
although all scales were focused on common OWS. All trials were randomized and six were 
double-blind while one trial employed a single-blind procedure. More than half of the trials used 
a standard of therapy for OWS as a comparator group or at baseline. Of note, an understanding 
of the natural course of opioid withdrawal, including that symptoms generally begin to decline 
after 3-5 days, is important to consider in evaluating the literature.  
1.2.1 Studies with a placebo comparator arm 
  Levo-tetrahydropalmatine (l-THP) 
         Levo-tetrahydropalmatine (l-THP) is a traditional Chinese herb believed useful for drug 
craving and relapse with no abuse potential.7 One study evaluated the use of l-THP for protracted 
opioid withdrawal syndrome (PAWS) after seven to ten days of detoxification among heroin 
users. Notably, participants were abstinent from opioids for at least seven days before beginning 
the trial. Subjects were randomized to receive 60 mg of l-THP or matching placebo twice daily 
for one month. Participants were evaluated for abstinence weekly through urine samples and for 
opioid withdrawal symptoms via the Heroin Withdrawal Scale during the active medication 
period and every two weeks thereafter for four months. The protracted abstinence withdrawal 
symptoms scale scored patients on symptoms in four categories: somatic, mood, insomnia, and 
heroin craving. The l-THP group had a lower retention rate at the two-week treatment mark 
compared to placebo. The participants who persisted in the trial were more likely to be abstinent 
after three months when compared to the placebo group, suggesting the first two weeks of 
therapy pose the greatest risk of relapse. Additionally, treatment with l-THP for one month was 
associated with a significant reduction in PAWS severity by the conclusion of the trial, 
specifically in regard to somatic syndrome, insomnia, and cravings. Study results indicated the 
 
importance of treatment past the typical one to two week window in which most patients 
experience withdrawal symptoms.  
Passionflower drops 
         Passionflower (Passiflora incarnata) vine is known for its anxiolytic and sedative effects, 
recognized by the Commission E in 1995 and the British Herbal Compendium in 1996.10 One 
trial investigated the use of passiflora extract as an adjunct to clonidine for outpatient 
detoxification.10 Thirty medically healthy men with opioid dependence as defined by DSM-IV 
were given 0.8 mg/day of clonidine divided into three daily doses and randomized to receive 
either 60 drops of passiflora extract or placebo three times daily for 14 days. The clonidine dose 
was tapered up from 0.3 mg/day to 0.8 mg/day in the first four days of the start of the trial. 
Further details of dosing were not provided by the study. Participants were assessed using the 
Short Opioid Withdrawal Scale (SOWS) expanded to include questions about mental symptoms 
and diarrhea. By day 14, both groups demonstrated a significant decrease in withdrawal 
symptoms based on the SOWS, but no significant difference was found between groups. 
However, a statistically significant difference was found between the two groups in regard to 
mental symptom scores, favoring the use of passiflora for mental symptoms, such as dysphoria, 
agitation, anxiety, and irritability. When taking into account SOWS scores, mental symptom 
scores, and diarrhea symptom scores, the placebo group had significantly increased mean total 
scores on day 14 than the passiflora group favoring the use of passiflora. Both the passiflora and 
placebo groups had large numbers of unexplained dropouts during the study, 15 and 20 
participants, respectively. This trial may be too small and inadequately powered to adequately 
demonstrate efficacy for the addition of passionflower drops to clonidine for OWS.  
 Dynorphin 
 
Dynorphin-(1-13) is a synthetic opioid agonist that has preliminary data on attenuating heroin 
withdrawal symptoms.11 In one trial, 18 men with longstanding heroin use were admitted to an 
inpatient care facility and randomized to one of three treatment groups upon demonstration of 
OWS.11 Two consecutive injections were given to patients one hour apart, either saline/saline, 
dynorphin/saline, or saline/dynorphin. The opioid withdrawal symptoms were scored using the 
Modified Kold and Himmelsbach procedure. Patients were scored for symptoms of opioid 
withdrawal every 15 minutes for one hour after each of the two injections. In both groups which 
received one 60 μg/kg injection of intravenous (IV) dynorphin, withdrawal scores were 
significantly decreased after injection. In the group that received a dynorphin injection first, 
saline did not result in any further lowering of opioid withdrawal score, however, scores 
remained low, suggesting a prolonged effect of dynorphin. In the group receiving the dynorphin 
injection second, withdrawal scores also decreased during the observation period. In regard to 
safety, three of the twelve patients displayed minor precordial formication, one reported feeling 
warm, and another dizzy.  
 
1.2.2 Studies with an active comparator arm: 
         Jinniu capsules 
         One trial investigated the safety and efficacy of Jinniu capsules, a traditional Chinese 
medicine product containing a blend of eight herbs, compared to lofexidine, an alpha-2 
adrenergic agonist, for OWS.6 Two hundred and twelve patients were randomized to a ten-day 
tapered regimen of Jinniu or lofexidine with tapering doses ranging from 7.5 g to 1.5 g/day and 
1.8 mg to 0.2 mg/day, respectively.  Supplemental medications were allowed, including the use 
of estazolam and clonazepam. Patients were assessed via an Opiate Withdrawal Scale, with an 
 
emphasis on drug craving, lacrimation, anxiety, diarrhea, abdominal pain, bone and muscle ache, 
and insomnia as well as the Hamilton Anxiety Scale.  Overall, opioid withdrawal symptoms and 
anxiety scale scores declined in the study and were similar between the groups. In terms of 
adverse events, Jinniu capsules were associated with blurred vision, dizziness, and dry mouth, 
while lofexidine was associated with dizziness, postural hypotension, and dry mouth. 
Fu-yuan pellet 
Fu-Yuan Pellet (FYP) is a ten herb traditional Chinese medicine product containing Largehead 
Atractylodes Rhizome, Hawthorn Fruit, Glabrous Greenbrier Rhizome, Tangshen, Prepared 
Dried Ginger, Eucommia Bark, Divaricate Saposhnikovia Root, Excrementum Pteropi, 
Desertliving Cistanche, and Dried Tangerine peel believed to be beneficial for OWS.8 One study 
compared the safety and efficacy of FYP versus lofexidine for symptoms of opioid withdrawal.8 
Two hundred and twenty-five participants were randomized to receive a ten-day taper of FYP 
with doses ranging from 24 g/day to 16 g/day or lofexidine 1.8 mg/day to 0.4 mg/day. The 23-
item withdrawal syndrome rating scale in the Principle of Clinical Trial 
of Anti-Opiate Withdrawal Drug was used to evaluate efficacy.9 Both treatments were 
considered effective as a score reduction of at least 50% was observed by the third day of 
treatment in both groups. Daily total scores, daily reduction rates, and total anxiety scale scores 
were similar between the two groups. Dry mouth was the most commonly reported adverse 
effect in both groups. Although lofexidine and FYP demonstrated similar efficacy, FYP was 
associated with significantly fewer adverse effects than lofexidine. 
Tai-Kang-Ning capsules 
         Another study evaluated Tai-Kang-Ning (TKN) capsules, a blend of eight herbs 
hypothesized to aid opioid addiction recovery, against lofexidine for symptoms of opioid 
 
withdrawal.12 Sixty-four patients with acute heroin withdrawal were randomized to receive either 
TKN in a regimen tapering the dosage from 6 g/day to 1.5 g/day or lofexidine tapered from 1.8 
mg/day to 0.2 mg/day. Patients were evaluated using a withdrawal syndrome rating scale. Both 
treatments were considered effective because a withdrawal symptom score reduction rate of over 
50% was observed by the third day of treatment in both groups. Furthermore, total scores for 
withdrawal syndrome decreased over the ten-day treatment course. Significant differences were 
not found between groups in either the daily total scores or the daily reduction rate.   
 WeiniCom capsules 
         WeiniCom, also known as Xuan Xia Qudu Jiaonang, is a blend of Chinese herbs 
including extracts of Glycyrrhiza glabra, Zingiber officinalis, Nauclea Spp, and Epimedium 
grandifora, among others. The product is believed to alleviate symptoms of opioid withdrawal in 
traditional Chinese and Ayurvedic medicine.13 One study evaluated the use of WeiniCom 
capsules compared to buprenorphine for the reduction in OWS and for adverse effects.14 Forty-
two subjects were randomized to treatment with either 8-10 capsules of WeiniCom four to six 
times daily, tapered to a dose of zero on treatment days nine and ten or buprenorphine 0.9-1.2 mg 
intramuscularly twice daily in tailored doses, tapered by 0.3 mg every other day until a dose of 
zero. In both arms, benzodiazepines (triazolam 0.75-2.5mg/day) were prescribed for patients 
with sleep problems or anxiety, the study reports that the use of benzodiazepines between groups 
was similar. Subjects were treated for 14 days. Both treatment and control groups experienced a 
decrease in Withdrawal Symptom Rating Scale scores and Craving Rating Scale scores over 
time. Significant differences between groups in regard to withdrawal symptoms were seen on 
days five, six, and nine of treatment in favor of WeiniCom. However, the assessments used were 
not validated at the time of the study. Furthermore, the trial failed to show significant findings 
 
consistently, rather, some treatment days were considered significant over others. These daily 
variances in significant findings have limited clinical applicability. 
  
1.3 Discussion: 
This systematic review was conducted to evaluate available evidence for the use of 
integrative medicine for the symptoms of opioid withdrawal. The integrative medicine 
approaches demonstrate potential benefits on selected symptoms of opioid withdrawal and in 
some studies, subsequent abstinence from opioid use, either as monotherapy or as an adjunct to 
clonidine, lofexidine, or buprenorphine.  Passiflora and Tai-Kang-Ni were evaluated as 
adjunctive medications while Jinniu capsules, Fu-Yuan pellets, and WeiniCom were compared to 
prescription medications as monotherapy. Levo-tetrahydropalmatine and dynorphin were 
compared as monotherapy to placebo arms. 
Both the intervention and comparator arms in each active-comparator trial included in 
this review demonstrated efficacy for opioid withdrawal symptoms, however the efficacy was 
often non-significant between study arms. Weinicom demonstrated significantly lower symptom 
scores than the comparator arm on multiple days, but the variances in statistical significance in 
day-to-day scores have limited clinical applicability. Similar safety profiles were seen for the 
integrative medicine approaches overall, except for Fu-Yuan pellets which had fewer adverse 
effects than the lofexidine comparator arm. A notable limitation of the active-comparator studies 
is the inadequate dosing of the comparator arms. For example, the lofexidine groups in the FYP, 
TKN, and Jinniu capsule trials may be considered underdosed. Current recommendations for the 
use of lofexidine in opioid withdrawal are 0.54 mg four times daily for five to seven days.16 The 
studies utilized lofexidine 0.6 mg three times daily as the maximum dose and this underdosing 
 
could contribute to a lack of significant findings. Additionally, the use of buprenorphine given as 
an intramuscular injection for OWS, as in the WeiniCom trial, is not indicated, thereby 
decreasing the trial’s potential applicability. Furthermore, a number of trials allowed adjuvant 
medications such as benzodiazepines for patients having insomnia or agitation. The addition of 
adjuncts on outcomes was not expressly evaluated and should be considered as a potential 
confounder to the use of integrative medicines. 
All of the placebo-comparator studies saw significant reductions in withdrawal symptoms 
of active treatment compared to placebo. The passionflower study suggested that passiflora may 
have favorable effects in regard to mental symptoms of opioid withdrawal specifically but 
concerns over the extensive number of unexplained dropouts may limit the applicability of the 
findings. The l-THP study found improvements in overall PAWS and abstinence rates at the end 
of the three month trial for those who continued after the first two weeks of treatment. In the 
dynorphin study, participants demonstrated significantly decreased withdrawal scores after 
dynorphin administration, however the small study population may hinder the reliability of these 
findings and the participants were following for no longer than two hours, the shortest followup 
of all the trials. In the passiflora and l-THP studies, data and discussion of adverse effects were 
lacking. The passiflora trial used clonidine in an appropriate dose, given current practice 
recommendations suggesting the use of clonidine in doses of 0.1 mg-0.2 mg two to four times 
daily.17 
Overall, multiple assessment scales with varied follow-up periods were used to determine 
effectiveness for physical and/or mental symptoms of withdrawal. A comparison between 
treatments is difficult given the differences in the assessment. For example, the OWS and Kolb 
& Himmelsbach procedures assess symptoms over a 24-hour period while the SOWS evaluates 
 
immediate responses.15 Thus, the definition of adequate follow-up for integrative medicine 
approaches remains uncertain. 
The participants in the trials varied in their duration of opioid use disorder, additional 
substance misuse, and time since last use. In general, trials had a small patient population 
composed primarily of men. Both the passionflower and dynorphin studies only used male 
participants, while the WeiniCom, l-THP, TKN, and Jinniu studies had 88%, 75%, 83%, and 
86% male participants, respectively. The FYP study did not delineate between male and female 
participants. Most of the trials had fewer than 100 participants and a short duration of follow up, 
warranting larger studies including a larger proportion of women to validate initial findings.  
Availability and feasibility of administration are also potential limitations of integrative 
medicine approaches. For example, of the approaches mentioned, dynorphin would be a more 
burdensome treatment option for patients because of the need for IV administration. The overall 
safety, efficacy, and availability of integrative medicines cannot be guaranteed given potential 
variances in the authenticity and purity of products resulting from a lack of governmental 
regulation and pharmacopeial standards. 
Preliminary literature searches identified a large body of evidence for the use of 
acupuncture to relieve opioid withdrawal symptoms. Because of the widespread availability of 
studies, systematic reviews, and meta-analyses involving acupuncture as well as the complexity 
of technique, those studies were excluded. Although this study aimed to evaluate lesser-known 
integrative medicine approaches, the elimination of analysis of acupuncture as an integrative 
medicine approach may be considered a limitation to this review. Additionally, despite the 
popularity of ibogaine and kratom, we did not identify studies with either natural product that 
met our inclusion criteria.  
 
Despite the limitations, integrative medicine may have the potential for alleviating opioid 
withdrawal symptoms. In general, outcome measures improved over time but were confounded 
by the natural course of opioid withdrawal resolution, specific characteristics of drug 
dependency, and individual determination in recovery. The results of this systematic review 
support the need for further research on integrative medicine for symptoms of opioid withdrawal.  
1.4 Conclusions: 
 Limited data demonstrates that integrative medicine has potential benefits in lessening 
opioid withdrawal symptoms without increasing the risk of adverse effects. Additional trials with 
larger patient populations are necessary to provide stronger evidence to support the use of 
integrative medicine approaches for OWS. Trials which focus on the feasibility of integrative 
medicine as monotherapy for outpatient treatment may be of particular value. Further research is 
necessary to adequately determine reliable approaches for opioid withdrawal symptoms.  
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